Video

Dr. Infante on the Future of BRAF Inhibitors in Melanoma

Author(s):

Jeffrey R. Infante, MD

Dr. Infante from Sarah Cannon Research Institute on the Future of BRAF Inhibitors in Melanoma

Jeffrey Infante, MD from Sarah Cannon Research Institute on the Future of BRAF Inhibitors in Melanoma

Related Videos
Dingwei Ye, MD, PhD
Areej El-Jawahri, MD, associate director, Cancer Outcomes Research and Education Program, director, Bone Marrow Transplant Survivorship Program, associate professor, medicine, Massachusetts General Hospital
Sandy Srinivas, MD
David Rimm, MD, PhD
Angeles A. Secord, MD, MHSc
Alexandra Drakaki, MD, PhD
Idoroenyi Amanam, MD
Sagar Lonial, MD, FACP
Leo I. Gordon, MD
Andrea Wolf, MD, MPH
Related Content
Richard Vile, PhD, Mayo Clinic
September 18th 2024

Understanding CAR T-Cell Therapy for Cancer: Mayo Clinic Expert Explains How It Works

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Dirk Schadendorf, MD
September 15th 2024

Early Switch Therapy to Atezolizumab After Vemurafenib/Cobimetinib Run-in Improves OS in BRAF V600–Positive Melanoma

Jeffrey S. Weber, MD, PhD
November 6th 2023

FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma

Caroline Robert, MD, PhD
September 15th 2024

Long-Term KEYNOTE-006 Data Support Pembrolizumab as SOC in Advanced Melanoma

James Larkin, MD
September 15th 2024

Nivolumab Alone, With Ipilimumab Demonstrate Sustained 10-Year Survival Benefit in Advanced Melanoma